Summary The biodistribution of no-carrier-added (n.c.a) meta-[131I]iodobenzylguanidine ([131I]MIBG) and that prepared by the standard isotopic exchange method were compared in athymic mice bearing SK-N-SH human neuroblastoma xenografts. No advantage in tumour uptake was observed for the n.c.a. preparation. BALB/c nu/nu mice exhibited lower uptake in highly innervated normal tissues (heart and adrenals) than normal BALB/c mice. In another experiment, the distribution of n.c.a.
Radioiodinated meta-iodobenzylguanidine (MIBG), which is an analogue of noradrenaline has found widespread application in the management of neuroendocrine tumours such as phaeochromocytoma and neuroblastoma (Feine et al., 1987; McEwan et al., 1985; Sisson et al., 1984; Troncone et al., 1987) . With regard to its diagnostic use, [1231] MIBG and ['1I]MIBG imaging has been found to be quite sensitive and specific for lesion localisation. For example, in the case of neuroblastoma, false-positive scans are virtually nonexistent and the number of false-negative scans is generally low (Mastrangelo, 1987) . Iodine-131-labelled MIBG is under active investigation for the targeted radiotherapy of neuroblastoma (Klingebiel et al., 1989; Garaventa et al., 1991) . The responses observed in some patients have been highly encouraging; however, it is clear that improvements in this treatment approach are needed.
One factor which could affect the efficacy of ['31I ]MIBG is the specific activity of the radiopharmaceutical. Radioiodinated MIBG, as currently used in the clinic, is prepared by an isotopic exchange method (Ex-['31I]MIBG) (Mangner et al., 1982) . This method yields preparations with a maximum specific activity of the order of 100 Ci mmol-1 and hence includes significant levels of carrier MIBG. For example, a typical therapy dose of ['1I ]MIBG contains about 200 ,ug of carrier MIBG per kg of body weight (Fielding et al., 1991) .
As MIBG is taken up in neuroblastoma cells in vitro and innervated tissues such as heart and adrenals in vivo primarily by a saturable mechanism (Wieland et al., 1981; Smets et al., 1989; Jaques et al., 1987) , one would expect that increasing the specific activity of radioiodinated MIBG could lead to an increase in tracer accumulation in target tissues. However, conflicting results on the effect of specific activity on MIBG distribution have been reported. For example, high and relatively constant myocardial uptake of [125I]MIBG was reported over a wide range of specific activity; however, the greatest heart accumulation was observed with the lowest specific activity (Wieland et al., 1981) ; similar behaviour was seen in the adrenals . On the contrary, saturation of heart uptake with low specific activity [231I]MIBG also has been reported in a subsequent study (Mock and Tuli, 1988) .
A number of laboratories have investigated the effect of specific-activity on the interaction of MIBG with tumour cells. In vitro studies using SK-N-SH human neuroblastoma cells have demonstrated that high specific activity ['3'I]MIBG was more cytotoxic than a low specific activity preparation at the same radioactivity dose level (Bruchelt et al., 1988) . However, in a preliminary report no significant difference in tumour uptake was observed in vivo between ['31I]MIBG preparations of high and low specific activities in mice bearing SK-N-SH xenografts (Rutgers et al., 1991) .
Recently, we have developed a no-carrier-added (n.c.a.) synthesis of radioiodinated MIBG Zalutsky, 1993, 1995) . With the availability of this labelling chemistry, investigations of the effect of specific activity on MIBG accumulation can now be extended to the n.c.a. level. We and others have shown that in vitro, the specific binding of n.c.a. [I31/125I]MIBG to human neuroblastoma cell lines remained constant over a 2-3-log activity range while that of Ex-['311125I]MIBG dropped by a factor of 7 (Vaidyanathan and Zalutsky, 1993; Mairs et al., 1995) , suggesting a lack of saturability for the n.c.a. preparation. The myocardial and adrenal uptake of the n.c.a. preparation was also found to be significantly higher than that observed for Ex- 
Results
The first biodistribution experiment was performed to compare the target and non-target organ uptake of n.c.a.
['31I]MIBG with that of an exchange preparation containing 2 pg of MIBG carrier. As summarised in Table I, both preparations were characterised by a rapid tissue clearance of 131 activity. Selective targeting in highly innervated normal tissues, i.e. heart and adrenals, was observed; however, the %ID g-1 levels were less than anticipated based on previous studies in normal mice. In general, no clear advantage was seen for the n.c.a. preparation. Except the 12 h time point, the heart uptake was similar for both preparations. The heart uptake of n.c.a. ['311 ]MIBG at 12 h (2.5+0.3%ID g-1) was slightly higher than that of exchange preparation (2.1 + 0.3 %ID g-) and the difference was statistically significant (P < 0.05). Adrenal uptake was also similar for both preparations except at 24 h, when that of Ex-['31I]MIBG was slightly higher (P < 0.05). Tumour weights determined at necropsy for the animals receiving n.c. normal BALB/c mice than in athymic BALB/c mice. For example, with the n.c.a. preparation, heart uptake at 4 h was 14.3 +2.8% ID/g in normal mice compared with 7.0+1.1% ID g-' for athymic animals (P<0.05). Heart uptake of the Ex preparation was also reduced in athymic mice, and in both species a myocardial delivery advantage was observed for n.c.a. ['31I]MIBG. Similarly, the adrenal uptake of both preparations in nude mice was significantly lower than in normal mice; however, within each species, no significant differences were seen when the uptake of two preparations in this tissue was compared. Unlike the previous study, thyroid uptake for n.c.a. ['3'I]MIBG (normal, 0.41 +0.09%; athymic, 0.48+0.12% at 1 h) was similar to that for Ex-['31I]MIBG (normal, 0.63+0.09%, athymic, 0.43+0.09%).
To confirm that differences in radiopharmaceutical (radiochemical purity, presence of unlabelled impurities) did not obscure potential specific activity related effects, an additional experiment was performed in which n.c.a. ['3'I]MIBG was administered alone, or with varying quantities of authentic MIBG carrier, to athymic mice with SK-N-SH xenografts. Carrier levels ranged from 3-9 jug per animal to encompass doses used in clinical therapy. As shown in Figure 2 , tumour uptake at both time points revealed small differences which were not statistically significant suggesting that unlabelled MIBG in this dose range has no effect on the tumour uptake. At both 4 and 24 h, the heart uptake was reduced by a factor of 1.5 by the addition of 3 ,ug of MIBG. A less dramatic effect was observed in adrenals; 6 jg of MIBG was necessary to cause a significant reduction at 4 h. At 24 h, no clear trend in adrenal uptake vs MIBG level was seen. With regard to normal tissues lacking a specific uptake mechanism for MIBG, no significant differences in uptake were seen among the four dose groups at either time point.
An additional group of tumour-bearing mice was injected with n.c.a. ['1'I]MIBG intravenously and ['251]MIBG by the intraperitoneal route and killed 24 h later. Although the tumour uptake when the activity was injected intravenously was about 50% higher than that for intraperitoneal administration (3.3+0.9% ID g-' vs 2.2+0.6% ID g-'), the difference was not statistically significant. With the exception of the stomach and intestines, which had higher uptake of the intraperitoneally administered radiopharmaceutical, no significant differences in MIBG uptake related to route of delivery were observed. [131I]MIBG in athymic mice bearing subcutaneous SK-N-SH human neuroblastoma xenografts in the absence (Z) and presence of various amounts of co-injected carrier MIBG (3 pg, B; 6 jg, E; 9 jug E).
Discussion
Improving the accumulation and retention of ['31I] (Mairs et al., 1995) .
In order to determine whether these differences were related to the presence of tumour or differences in mouse strain, an experiment was performed in which the same n.c.a. and Ex-[13'I]MIBG preparations were administered to BALB/ c normal and athymic mice. Even in nu/nu mice without neuroblastoma xenografts, tracer accumulation in heart and adrenals was lower than that in normal animals. However, it is important to note that the magnitude of the differences was considerably less than seen in comparing normal mice with tumour-bearing animals. As one would expect, within the same species, carrier did reduce the myocardial uptake considerably; however, carrier MIBG did not alter the adrenal uptake to a significant degree.
The reduced uptake of ['31I ]MIBG in the heart in tumourbearing mice can probably be explained by the competition of elevated levels of endogenous catecholamines secreted by the tumour which could block ['3'1]MIBG uptake in innervated tissues. Several groups have observed that the presence of neuroblastoma tumours in mice results in 3-to 10-fold higher levels of dopamine-p-hydroxylase, the enzyme that catalyses the conversion of dopamine to noradrenaline (Anagnoste et al., 1972; Helson, 1975) . In human phaeochromocytoma patients, reduction in myocardial uptake of radioiodinated MIBG has been observed, and this has been attributed to elevated levels of catecholamines (Nakajo et al., 1983a, b) .
Elevated levels of biogenic amines in the serum of tumourbearing mice appears to be a reasonable explanation for the reduced heart uptake observed in these animals; however, it does not account for the results which were obtained in athymic mice without tumours. While it may be intriguing to speculate that the catecholamine levels in normal and athymic mice may be different, unfortunately, no data are available from these animals to confirm this possibility.
The most significant observation from the current study is that Another variable to be considered is differences in the noradrenaline transporter (NAT), which is responsible for the saturable, specific uptake of MIBG in neuroblastomas (Bruchelt et al., 1995) . The expression of this transporter in neuroblastoma may be regulated by many factors which can act differently in different cell lines. An inverse correlation between the expression of NAT and tyrosine hydroxylase, the key regulatory enzyme of the catecholamine synthesis, has Specific activity effect on MIBG uptake G Vaidyanathan et al 1176 been observed for SK-N-SH cells (Bruchelt et al., 1995) . It may be possible that the expression of NAT gene is diminished for SK-N-SH cells when implanted in vivo. Indeed, preliminary experiments using semiquantitative reverse transcription polymerase chain reaction mechanism is shut off in our model. If the majority of the MIBG was taken up by passive diffusion, a phenomenon favourable at higher concentrations, added carrier, as seen in this study, could enhance the uptake.
In conclusion, our results indicate no advantage for higher specific activity preparations of ['3'I]MIBG in the SK-N-SH human neuroblastoma xenograft model. Further investigations are needed in other xenograft models to clarify the factors accounting for this behaviour, particularly since the utility of the SK-N-SH cell line as a model for neuroblastoma has been questioned . In addition, we will soon be initiating clinical evaluation of n.c.a. ['231 ]MIBG in patients with neuroendocrine tumours to determine whether this radiopharmaceutical offers a practical advantage in enhancing tumour localisation.
